Introduction
============

Son of Sevenless 1 (SOS1) has a central role in signal transduction from receptor tyrosine kinases (RTKs) to small G proteins RAS and RAC.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ Structural and biochemical studies revealed that SOS1 is a multi-domains protein with extensive intramolecular interaction that tightly constrains its activity.^[@bib5]^ For example, SOS1 possesses two binding sites for RAS, one of which is an allosteric site that is distal to the active one.^[@bib6]^ Binding of active RAS at this site stimulates the nucleotide-exchange activity of SOS1 by causing conformational changes that allow substrate RAS to bind.^[@bib2],\ [@bib7],\ [@bib8],\ [@bib9]^

An additional important domain is the DH-PH (Dbl and Pleckstrin Homology domain), which is a structural hallmark for exchange factors of the Rho family of GTPases, and was proposed to act as a RAC-specific guanine nucleotide exchange factor (GEF).^[@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19],\ [@bib20]^ However, the DH-PH unit is folded into a closed conformation, implying that SOS1 RAC GEF activity is auto-inhibited and requires specific molecular events to be activated.^[@bib8],\ [@bib21],\ [@bib22]^ Two distinct mechanisms of SOS1 activation have been proposed: SOS1 must assemble into a multimolecular complex with EPS8, ABI1 to become catalytically active.^[@bib12],\ [@bib17],\ [@bib18],\ [@bib19],\ [@bib20]^ The second mechanism, instead, involves tyrosine phosphorylation of SOS1 by ABL kinase.^[@bib15]^ However, how tyrosine phosphorylation induces SOS1 RAC GEF activity and its pathophysiological relevance remains ill defined.

Physiologically, ABL kinase participates in RTK-induced actin cytoskeleton remodeling, a signaling pathway in which the function of the SOS1-RAC axis is pivotal.^[@bib15]^ Hyperactive, uncontrolled kinase activity of ABL is also responsible for its oncogenic potential. The p210-BCR-ABL fusion oncoprotein is indeed necessary and sufficient to cause chronic myelogenous leukemia.^[@bib23],\ [@bib24]^ Although the role of BCR-ABL in chronic myelogenous leukemia has been well studied, the critical signaling pathways mediating its transforming ability are incompletely clarified. Among them, the one leading to the activation of RAC GTPases critically mediates BCR-ABL transformation.^[@bib25],\ [@bib26],\ [@bib27]^ Indeed, RAC3, one of the three mammalian RAC isoforms, is activated in p190-BCR-ABL malignant precursor B-lineage lymphoblast and its removal increases survival in p190-BCR-ABL-transgenic, RAC3-null mice (a model of acute lymphoid leukemia).^[@bib28]^ In addition, the ubiquitously expressed RAC1 and hematopoietic-restricted RAC2 were shown to be critical for p210-BCR-ABL-mediated leukemogenesis and myeloproliferative disease.^[@bib29]^ How RAC becomes activated by ABL thus becomes a key question to be addressed. SOS1, which is expressed in myeloid cells and is regulated by ABL,^[@bib15]^ may serve this role.

Here we show that phosphorylation of Y1196 on the C-terminal proline-rich region of SOS1 is sufficient to elicit its RAC GEF activity *in vitro* and *in vivo* in response to the activation of various receptor and non-RTKs, including ABL. We further demonstrate that Y1196 of SOS1 is phosphorylated in BCR-ABL leukemic human and murine blasts, and is required for full RAC activation, cell proliferation and transformation *in vitro* and in mouse models. Genetic removal of SOS1 delays the onset of BCR-ABL leukemogenesis.

Materials and methods
=====================

Materials and methods are described in details in [Supplementary Information](#sup1){ref-type="supplementary-material"}.

Results
=======

SOS1 is tyrosine phosphorylated on Y1196 *in vitro*
---------------------------------------------------

To investigate the molecular, biochemical and functional consequences of ABL-mediated tyrosine phosphorylation of SOS1 we sought to identify the target tyrosine(s). As an initial approach, we subjected full-length SOS1 and various recombinant shorter fragments to an *in vitro* kinase assay with ABL kinase ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"} (top)). Only the fragment encompassing the C-terminal proline-rich region was efficiently tyrosine phosphorylated ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}), hence restricting the region targeted by ABL.

Next, we used *in vitro* tyrosine phosphorylated SOS1 and titanium oxide-based affinity chromatography to enrich for phosphorylated peptides coupled with nano liquid chromatography--tandem mass spectrometry analysis^[@bib30],\ [@bib31]^ ([Figure 1a](#fig1){ref-type="fig"}). We generated a peak list, which was searched against the IPI human database using Mascot 2.0 (Matrix Science Inc., Boston, MA, USA). However, no pY-containing peptide could be identified automatically by Mascot search, but spotted instead by searching the MS/MS data set for pTyr immonium ion at *m*/*z* 216.043^(refs\ [@bib32],\ [@bib33])^ and subsequently sequenced manually. This procedure revealed Y1196, located in the proline-rich C-terminus of SOS1, as the major putative ABL kinase target ([Figure 1a](#fig1){ref-type="fig"}). We validated this result using two-dimensional phospho-peptide mapping that revealed a single, major phosphorylated spot derived from WT-SOS1, but not from Y1196F-SOS1 mutant ([Figure 1b](#fig1){ref-type="fig"}). Thus, tyrosine 1196 is the major ABL phosphorylation site of SOS1 *in vitro*.

SOS1 is tyrosine phosphorylated on Y1196 *in vivo*
--------------------------------------------------

To assess whether Y1196 is phosphorylated *in vivo*, we undertook two distinct approaches. First, we ectopically expressed WT-SOS1 or Y1196F-SOS1 mutant in combination with an activated form of ABL (ABL-ΔSH3)^[@bib34]^ in 293T cells. Immunoblotting with anti-pY antibodies of SOS1 immunoprecipitates revealed that tyrosine phosphorylation of Y1196F-SOS1 was significantly reduced with respect to WT-SOS1 ([Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}). Next, we raised monoclonal, anti-pY1196 antibodies the specificity of which was tested using WT- and Y1196-SOS1 in various assays ([Supplementary Figures S2A and B](#sup1){ref-type="supplementary-material"}). We detected Y1196 phosphorylation in lysates of cells expressing activated ABL and WT-SOS1, but not Y1196F-SOS1 mutant, both when we immunoprecipitated total SOS1 with anti-hemagglutinin (HA) antibody, followed by immunoblotting with anti-pY1196 or vice versa ([Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}). In addition, as SOS1 and ABL act on RTK-dependent signaling pathways,^[@bib15],\ [@bib35],\ [@bib36]^ we found that platelet-derived growth factor (PDGF) stimulation efficiently phosphorylated endogenous SOS1 on Y1196 in mouse embryo fibroblasts (MEFs) ([Supplementary Figure S3B](#sup1){ref-type="supplementary-material"}). Similarly, stimulation of ERBB family members with either Heregulin or epidermal growth factor in breast cancer cell lines increased Y1196-SOS1 phosphorylation, which was abrogated by the ABL kinase inhibitor Imatinib (STI571) ([Supplementary Figure S3B](#sup1){ref-type="supplementary-material"}). We concluded that phosphorylation of Y1196 occurs physiologically in response to a variety of RTK-dependent stimuli, presumably through ABL kinase activity.

Phosphorylation of Y1196 is sufficient to promote the exchange of nucleotides on RAC1, but not on H-RAS *in vitro*
------------------------------------------------------------------------------------------------------------------

Next, we tested GEF activities on RAC1 and H-RAS of tyrosine-phosphorylated SOS1. Tyrosine-phosphorylated SOS1, purified from cells co-expressing activated ABL, but not Y1196F-SOS1 mutant, displayed detectable RAC1-GEF activity in *in vitro* assays ([Supplementary Figures S4A and B](#sup1){ref-type="supplementary-material"}). Importantly, under the same conditions, WT- and Y1196F-SOS1 showed similar levels of H-RAS-GEF activity, indicating that tyrosine phosphorylation specifically affects RAC1, but not H-RAS-GEF activity ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}). To confirm that the Y1196F mutation abrogates ABL-mediated SOS1 RAC1 GEF activity, we performed a double affinity purification of SOS1 from lysates of cells expressing activated ABL and SOS1 using a GRB2-GST column in tandem with an anti-pY1196 antibody-protein G-sepharose column ([Supplementary Figure S4C](#sup1){ref-type="supplementary-material"}). The final elution step with phosphorylated antigenic SOS1 peptides yielded highly purified pY1196-SOS1 ([Supplementary Figure S4C](#sup1){ref-type="supplementary-material"}). Using a fluorescent-nucleotide-based RAC1-GEF assay, we showed that pY1196-SOS1 promoted guanine nucleotide exchange on RAC1 at catalytic concentrations, similar to the DH-PH domain of TIAM1, used as positive control ([Figure 2a](#fig2){ref-type="fig"}). Finally, dephosphorylation of pY-SOS1 with a tyrosine-specific phosphatase abrogated its RAC1-GEF activity ([Figure 2b](#fig2){ref-type="fig"}). Thus, tyrosine-phosphorylated SOS1 acts as a RAC1-GEF *in vitro*.

SOS1 inter-molecular interaction is inhibited by activated ABL
--------------------------------------------------------------

These findings raise the question as to the underlying molecular mechanism. Crystallization studies revealed that SOS1 is engaged into extensive intra-molecular and possibly inter-molecular interactions.^[@bib8],\ [@bib37]^ However, none of the solved structures of SOS1 includes the proline-rich region, which contains Y1196. We hypothesized that also this region undergoes intramolecular or intermolecular interactions with other SOS1 domains. We initially tested the ability of various, immobilized SOS1 fragments to bind the soluble proline-rich region in far western assays. We found that SOS1 proline-rich region binds with a micromolar (apparent) affinity to its DH-PH domain and further restricted the region of interaction to the PH domain ([Supplementary Figures S5A--C](#sup1){ref-type="supplementary-material"}). The SOS1 PH domain has been proposed to exert an inhibitory effect on the DH domain by blocking its accessibility to RAC1.^[@bib22]^ A significant change in the fold must therefore be invoked for this domain to become catalytically active. Loss of binding of the proline-rich region to the DH-PH domain may be implicated in initiating these structural changes. We thus performed a binding assay between the DH-PH domain and either the phosphorylated or a non-phosphorylated Y1196-containing peptide. The phosphorylated peptide bound the DH-PH domain with a much lower apparent affinity (*K*~d~\>200 μ[M]{.smallcaps}), as compared with the non-phosphorylated peptide (*K*~d~\~30 μ[M]{.smallcaps}) ([Supplementary Figure S5D](#sup1){ref-type="supplementary-material"}). These findings are also compatible with the possibility of *trans* rather than *cis* interaction between two SOS1 molecules, where the proline-rich region of one molecule may bind to the DH-PH domain of the other. If this was the case, then a fraction of SOS1 may form dimers, as previously suggested,^[@bib37]^ whose stability should be controlled by Y1196 phosphorylation. Consistently, by exploiting differentially HA- and green fluorescent protein (GFP)-tagged SOS1 constructs, we showed that: (i) a sizable fraction of HA-tagged SOS1 co-immunoprecipated with GFP-SOS1 ([Supplementary Figure S5E](#sup1){ref-type="supplementary-material"}); (ii) the concomitant expression of an activated ABL robustly reduced this inter-molecular interaction ([Supplementary Figure S5E](#sup1){ref-type="supplementary-material"}); and (iii) mutation of Y1196F that prevents ABL-mediated phosphorylation and the acquisition of RAC1-GEF activity also inhibited the inter-molecular interaction ([Supplementary Figure S5F](#sup1){ref-type="supplementary-material"}). These results indicate that SOS1 needs to be in its tyrosine phosphorylated, monomeric form to act as RAC1 GEF. A corollary of this mode of action is that a SOS1-Y1196F mutant should not only be deficient in RAC1 activation *in vitro* (as we showed above), but may also act as a dominant negative. Consistently, the expression of SOS1-Y1196F completely inhibited RAC1-GTP levels in SOS1 proficient cells, acting in a dominant-negative manner ([Supplementary Figure S5G](#sup1){ref-type="supplementary-material"}).

Although more work is needed to precisely decipher the sequence of molecular events, the sum of this finding indicates that tyrosine phosphorylation of Y1196 promotes the dissociation of SOS1 inter-molecular interaction, resulting in the formation of monomers which, either alone or through subsequent incorporation into larger molecular weight complexes (see Discussion), leads to optimal activation of SOS1 RAC1-GEF.

Phosphorylation of SOS1 Y1196 is required for optimal PDGF-dependent activation of RAC1, RAC1-dependent actin remodeling and migration
--------------------------------------------------------------------------------------------------------------------------------------

To validate the physiological relevance of Y1196 phosphorylation of SOS1 in controlling the activation of RAC, we measured the cellular levels of GTP-bound RAC. Initially, we used cells co-expressing either WT- or Y1196F-SOS1 together with activated ABL. Activated ABL increased RAC1-GTP levels, which are not significantly altered by the concomitant expression of SOS1, indicating that the latter protein is not a limiting factor in this pathway ([Supplementary Figure S6A](#sup1){ref-type="supplementary-material"}). Conversely, co-expression of activated ABL and Y1196F-SOS1 robustly reduced ABL-mediated RAC activation ([Supplementary Figure S6A](#sup1){ref-type="supplementary-material"}), consistent with Y1196F-SOS1 exerting a dominant-negative function.

Next, we assessed whether this posttranslational modification had an impact on RAC activation in response to PDGF stimulation^[@bib15],\ [@bib35]^ using *Sos1*−/− MEFs reconstituted with either WT- or Y1196F-SOS1 ([Supplementary Figure S6B](#sup1){ref-type="supplementary-material"}). *Sos1*−/− MEF showed reduced RAC-GTP levels as compared with *Sos1*−/− MEF reconstituted with WT-SOS1 ([Figure 3a](#fig3){ref-type="fig"}). Conversely, the expression of Y1196F-SOS1 did not restore RAC activation ([Figure 3a](#fig3){ref-type="fig"}). Notably, PDGF-induced ERK and AKT activities were unaffected by either SOS1 removal or the expression of Y1196F-SOS1 mutant ([Supplementary Figure S6C](#sup1){ref-type="supplementary-material"}). In agreement with the observation that pY1196 of SOS1 mediates not only RAC activation, but also PDGF-induced, RAC-dependent actin remodeling, *Sos1*−/− MEFs were impaired in the formation of PDGF-induced circular dorsal ruffles ([Figure 3b](#fig3){ref-type="fig"}), where SOS1 localizes ([Supplementary Figure S6D](#sup1){ref-type="supplementary-material"}). Circular dorsal ruffles are RAC-dependent migratory and endocytic structures that mark the acquisition of a mesenchymal mode of cell locomotion.^[@bib38]^ This response was restored by WT-SOS1, but not Y1196F-SOS1 ([Figure 3b](#fig3){ref-type="fig"}). Notably, Y1196F-SOS1 expression not only failed in rescuing circular dorsal ruffle, but also inhibited their formation ([Figure 3b](#fig3){ref-type="fig"}). The specific requirement of SOS1 as a RAC-GEF in PDGF-induced actin remodeling is underscored by the finding that functional interference with VAV, a RAC-GEF family protein regulated by tyrosine phosphorylation, had no effect on circular dorsal ruffle formation ([Supplementary Figure S6E](#sup1){ref-type="supplementary-material"}). Finally, *Sos1*−/− MEFs were impaired in cell motility, which was increased by the expression of WT, but not of Y1196-SOS1 ([Supplementary Figure S6F](#sup1){ref-type="supplementary-material"} and [Supplementary Movie S1](#sup1){ref-type="supplementary-material"}). Thus, SOS1 and phosphorylation of Y1196 are required for optimal RAC1 activation and RAC1-dependent actin remodeling and cell motility in response to PDGF stimulation.

SOS1 is phosphorylated by oncogenic BCR-ABL in leukemic blast and is required for BCR-ABL-mediated full transformation
----------------------------------------------------------------------------------------------------------------------

We next assessed whether phosphorylation of SOS1 Y1196 might also be critical in pathological conditions characterized by a hyperactive ABL kinases activity. The fusion oncoprotein BCR-ABL originating from a balance chromosome translocation leading to chronic myelogenous leukemia is a case in point.^[@bib39]^ Among BCR-ABL-stimulated oncogenic pathways the one leading to activation of RAC proteins has been shown to be pivotal for full transformation.^[@bib25],\ [@bib29],\ [@bib40]^ We thus tested whether SOS1 contributes to BCR-ABL-mediated RAC activation and transforming potential. Using pY1196-phospho-specific antibody, we showed that SOS1 is tyrosine phosphorylated in K562, a human cell line derived from a chronic myelogenous leukemia patient, and in BCR-ABL-expressing murine hematopoietic progenitor 32D cell line ([Supplementary Figures S7A and B](#sup1){ref-type="supplementary-material"}). The administration of the ABL kinase inhibitor STI571 abolished SOS1 phosphorylation in both cell lines ([Supplementary Figure S7B](#sup1){ref-type="supplementary-material"}). Next, we generated K562 cells stably knocked down for SOS1 (SOS1-KD) with three independent short hairpin RNAs (see also [Supplementary Methods](#sup1){ref-type="supplementary-material"}). SOS1 silencing reduced RAC-GTP levels, similar to STI571 treatment ([Figure 4a](#fig4){ref-type="fig"}), but had no impact on ERK1/2 activity ([Supplementary Figure S7C](#sup1){ref-type="supplementary-material"}). In addition, SOS1-KD K562 cells had a significantly reduced rate of proliferation compared with scramble-transfected control cells ([Figure 4b](#fig4){ref-type="fig"}), but similar to the one achieved by treatment with the RAC inhibitor, NSC27633 ([Figure 4b](#fig4){ref-type="fig"}). Notably, treatment with STI571 was, as expected,^[@bib39]^ more effective in reducing cell proliferation ([Figure 4b](#fig4){ref-type="fig"}), also as a consequence of increase cell death, which instead was not observed after SOS1 removal or RAC inhibition ([Supplementary Figure S7D](#sup1){ref-type="supplementary-material"}). The slower proliferation rate of SOS1-KD K562 cells was also accompanied by increased expression of hemoglobin, a prototypical erythroid marker ([Supplementary Figure S7E](#sup1){ref-type="supplementary-material"}).

Next, we tested weather SOS1 ablation impairs transformation and tumorigenesis. In soft agar growth assays, under conditions in which STI571 treatment completely abrogated transformation, SOS1 silencing significantly reduced both the number and the size of colony as compared with untreated, control K562 cells ([Figure 4c](#fig4){ref-type="fig"}). In xenotransplantation mouse model, NOD/SCID mice injected with control K562 rapidly died due, as expected ([Figure 4d](#fig4){ref-type="fig"}), to the expansion of leukemic blasts (not shown). The removal of SOS1 from K562 cells drastically increased mice survival ([Figure 4d](#fig4){ref-type="fig"}).

To provide direct evidence that the above phenotypic alterations are caused by the loss of *Sos1* and of Y1196 phosphorylation, we restored the expression of either WT- or Y1196F-SOS1 mutant into SOS1-KD K562 cells using short hairpin RNA-resistant variants fused to GFP. GFP-WT and GFP-Y1196F-SOS1 expression levels were comparable to those of endogenous SOS1 of control K562, whereas endogenous SOS1 levels in the ectopically reconstituted cells remain significantly downregulated ([Supplementary Figure S8A](#sup1){ref-type="supplementary-material"}). Re-expression of WT-SOS1, but not of Y1196F-SOS1 mutant, reduced hemoglobin, suggesting that differentiation blockade was restored ([Supplementary Figure S8A](#sup1){ref-type="supplementary-material"}), restored RAC-GTP levels ([Supplementary Figure S8B](#sup1){ref-type="supplementary-material"}), cell proliferation ([Supplementary Figure S8C](#sup1){ref-type="supplementary-material"}) and transformation potential ([Supplementary Figure S8D](#sup1){ref-type="supplementary-material"}).

The transient nature of SOS1 knocked down and Y1196F re-expression, which were counter selected and lasted only for a limited number of passages (similar data were obtained using CRISPR-SOS1-KO K562 cells---not shown), prevented us to assess whether also *in vivo* we could restore leukemogenesis. To overcome this limitation, we employed a murine model in which the loss of *Sos1* can be induced by tamoxifen-mediated CRE recombination (herein on referred to as *Sos1*^fl^/^fl^).^[@bib41]^ bone marrow-derived cell (BMDC) from control and *Sos1*^fl^/^fl^ mice were retro-virally infected with EGFP-p210-BCR-ABL-fusion gene-expressing retroviral vectors (MigBCR-ABLp^210^), treated with tamoxifen to induce *Sos*1 deletion and tested *in vitro* and *in vivo* to assess BCR-ABL transforming and leukemogenic ability ([Figure 5](#fig5){ref-type="fig"}). Consistent with the results obtained with human K562 cells, genetic removal of *Sos1* significantly reduced colony formation ([Supplementary Figure S9A](#sup1){ref-type="supplementary-material"}), without altering the immunophenotypes of BCR-ABL-transformed *Sos1* null BMDC as compared with control cells ([Supplementary Figure S9A](#sup1){ref-type="supplementary-material"}). More relevantly, tamoxifen-mediated *Sos1* loss of BCR-ABL-infected *Sos1*^fl^/^fl^ BMDC significantly delayed the development of leukemia upon BMDC transplantation into recipient mice ([Figures 5a and c](#fig5){ref-type="fig"}), without affecting engraftment ([Supplementary Figures S9B and C](#sup1){ref-type="supplementary-material"}) and stemness potential of the leukemic cells ([Supplementary Figures S9E--G](#sup1){ref-type="supplementary-material"}).

Collectively, our result supports the notion that SOS1 is phosphorylated by oncogenic BCR-ABL in leukemic cells, is required for BCR-ABL-mediated full transformation and contributes to leukemogenesis.

Discussion
==========

In this work, we provide evidence that SOS1 is phosphorylated by ABL on Y1196. This post-translational modification endows SOS1 with the capacity to activate RAC in response to physiological stimulation of RTKs and in BCR-ABL pathological context. In the former, case an RTK-ABL-pY1196-SOS1 pathway operates to control RAC-mediated actin-based protrusions leading to enhanced directed migration, consistent with a role of ABL and RAC in these processes.^[@bib42],\ [@bib43]^ A BCR-ABL-pY1196SOS1-RAC axis is instead critical to promote full transforming and leukemogenic ability of the fusion protein.

Our findings are of relevance both for the understanding of the molecular mechanisms through which SOS1 RAC-GEF activity is controlled and further unveil an unexpected role of SOS1-RAC in BCR-ABL transformation. How SOS1 acquires RAC-GEF activity has remained elusive and difficult to reconcile with the finding that the isolated DH-PH domain of SOS1 folds into a catalytically inactive conformation.^[@bib22],\ [@bib37]^ A substantial conformational change of the DH-PH domain must occur for SOS1 to become catalytically proficient. Our findings suggest that phosphorylation of Y1196 may be a way to promote such structural rearrangements. Consistently, we found that the isolated proline--rich region binds directly to the DH domain through residues encompassing Y1196. In addition, phosphorylation of Y1196 reduces this interaction, induces SOS1 RAC-GEF *in vitro* and is required to elevate RAC-GTP levels *in vivo*. Thus, although we cannot exclude that Y1196 might be the binding site of yet-to-be found regulators of SOS1, a plausible possibility is that phosphorylation of this tyrosine is necessary to liberate an inhibitory molecular proline-rich/DH-PH interaction. The latter interaction may not necessarily occur intra-molecularly and might drive the formation of inter-molecular interactions. Within this context, ABL-mediated phosphorylation of Y1196 disrupt this linkage, leading to liberation of monomeric SOS1, which may, in turn, become incorporated into large macromolecular complex, necessary for full activation of its RAC1 GEF. Indeed, we have previously shown that one additional way to modulate SOS1 RAC-GEF is via assembly into a macromolecular complex that contains EPS8 and ABI1.^[@bib12],\ [@bib18],\ [@bib19]^ Intriguingly, the latter protein is an interactor and activator of ABL,^[@bib44],\ [@bib45]^ suggesting that SOS1 tyrosine phosphorylation may ensue following the assembly of this complex. In keeping with this notion, preliminary evidence indicates that ABL co-immunoprecipates with SOS1 and EPS8 in an ABI1-dependent manner. Under this condition, ABL activity is elevated and SOS1 becomes phosphorylated on tyrosine: an event that might be critical for promoting the RAC-GEF activity of the macromolecular complex.

Biochemical and genetic studies in mice models have unequivocally shown that the RAC GTPases are critical downstream signaling targets used by BCR-ABL to promote its full leukemogenic and transforming potential.^[@bib25],\ [@bib28],\ [@bib29],\ [@bib40],\ [@bib46]^ Mechanistically, the GEFs VAV1, 2 and 3 have been shown to biochemically link BCR-ABL to RAC proteins.^[@bib47]^ Indeed, VAV proteins are tyrosine phosphorylated and activated by ABL.^[@bib42],\ [@bib47],\ [@bib48]^ Their genetic loss, however, results in complex BCR-ABL-dependent pathological phenotypes and delays, but does not abrogate BCR-ABL leukemogenesis,^[@bib49]^ suggesting that other GEFs must have important roles. Our findings are consistent with the latter notion by showing that SOS1 is one additional critical exchange factors mediating BCR-ABL-dependent activation of RAC proteins and transforming ability. In none of our assays, we could distinguish whether tyrosine phosphorylated SOS1 displays any preference for the different RAC proteins. However, it would not be unfeasible that different GEFs target specific GTPases (different RACs in this case), in turn required to control a define set of biological outputs. In support of this contention, we noticed, that both RAC2 and VAV3 deficiency reduced cell proliferation and increased apoptosis, possibly interfering with phosphorylation of the pro-apoptotic BAD protein.^[@bib40],\ [@bib49]^ Loss of *Sos1* instead reduces cell proliferation, but has no effect on apoptosis, while pushing K562 cells to acquire expression of hemoglobin. K562 cells are bipotent progenitor cells, which are blocked in the differentiation program due to the expression of the BCR-ABL.^[@bib50]^ Thus, removal of SOS1 may induce these cells to acquire erythrocyte lineage properties, suggesting that SOS1 is required for cell proliferation and possibly for the maintenance of a more undifferentiated state rather than controlling apoptosis.

In summary, our data reveal a novel molecular mechanism through which the poorly studied SOS1 RAC-GEF activity becomes activated by BCR-ABL, contributing to its pathogenic, transforming functions. They further suggest that targeting this interaction and signaling axis might be beneficial in combination with BCR-ABL pharmacological treatment to prevent or delay the onset of BCR-ABL resistance, at least in part, by reducing the proliferation potential of leukemic progenitors.
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![Tyrosine 1196 of SOS1 is the major target residue of ABL kinase. (**a)** SOS1 immuno-purified from SOS1-expressing 293T cells (1 mg lysates) with an anti-SOS1 antibody was *in vitro* phosphorylated with ABL kinase, resolved on SDS-Page and detected by Coomassie staining or by immunoblotting (IB) using the indicated antibody. SOS1 band was digested with trypsin. Phosphorylated peptides were enriched with titanium oxide beads and analyzed by tandem mass spectrometry. Left: the diagram shows the detected fragments of the phosphorylated pYSISDR peptide. Fragments are presented according to their mass/charge ratio (*m*/*z*) and their intensity (relative abundance). The intensity of the highest peak corresponds to a relative abundance of 100%. *Right*: The possible fragmentation of the peptide is shown. The peak (pY) in the diagram (left) with an m/z of 216,07 corresponds to the a~1~ fragment on the right. Mw markers are indicated on the side of the immunoblots. (**b**) WT-SOS1 and Y1196F-SOS1 immunopurified from SOS1-overexpressing 293T cells (1 mg lysate) were incubated in the presence or absence (Control) of ABL kinase and ^32^P-ATP and subjected to SDS-polyacrylamide gel electrophoresis. After PonceauS staining, the SOS1 band was excised and digested with trypsin. Oxidized peptides were separated by electrophoresis and thin layer chromatography.](leu2017267f1){#fig1}

![Phosphorylation of Y1196 by ABL is sufficient to elicit SOS1 RAC GEF activity. (**a** and **b**). MANT-GDP-fluorescence RAC GEF assay of purified pY1196F-SOS1. GST-RAC1 was equilibrated with 2 μ[M]{.smallcaps} MANT-GDP. After 300 s, we added: (**b**) purified, phospho-enriched SOS1 (30 μl and 120 μl, corresponding to \~10 and 40 n[M]{.smallcaps}, respectively) or 50 n[M]{.smallcaps} of His-DH-PH of Tiam1 (used as positive control). Buffer indicates the non-stimulated nucleotide exchange rate of RAC1; left panels, purified, phospho-enriched SOS1 or un-phosphorylated SOS1 (treated with T-cell-specific tyrosine phosphatase either in the presence (TCI) or the absence (TC) of T-cell phosphatase inhibitor). The reaction containing MANT-GDP was excited at 360 nm. The emission of MANT-GDP-bound to RAC was measured at 440 nm. Right panels: aliquots of phosphorylated (TCI) and phosphatases dephosphorylated (TC) SOS1 was immunoblotted with the antibodies indicated on the right.](leu2017267f2){#fig2}

![Phosphorylation of SOS1-Y1196 is required to promote optimal RAC activation, RAC-dependent actin remodeling in fibroblasts in response to PDGF. (**a**) Wild type, but not Y1196F-SOS1, reconstitutes RAC activation in *Sos1*−/− MEFs. Serum-starved *Sos1*−/− MEFs, reconstituted with HA-WT-SOS1 or HA-Y1196F-SOS1 (YF) or empty vector, as control (Ctr) (see [Supplementary Figure S6A](#sup1){ref-type="supplementary-material"}), were stimulated with 10 ng/ml of PDGF for 7 min. Activated RAC-GTP was pulled down from 1 mg of total lysates using 20 μg of recombinant GST-CRIB. Lysates (20 μg) and bound proteins were immunoblotted with the indicated antibodies. (**b**) Serum-starved *Sos1*−/− MEFs, reconstituted with HA-WT-SOS1 or HA-Y1196F-SOS1 or empty vector (Ctr), were stimulated with 10 ng/ml of PDGF for 7 min. Cells were stained for F-actin with Tritc-Phalloidine. The number of cells with circular dorsal ruffle (CDR) is expressed as percent of total. At least 100 cells were scored for each condition. The data represents the mean±s.e.m (*n*=4 performed in triplicates). Right panels: representative pictures of MEFs forming CDR. Scale bar, 40 μm.](leu2017267f3){#fig3}

![SOS1 phosphorylation is required for RAC1 activation and BCR-ABL-mediated full transformation. (**a**) K562 cells infected with pSuperRetroPuro Control vector (Ctr) or pSuperRetroPuro SOS1 interfering vector (SOS1-KD) were treated for 10 min with 10 μ[M]{.smallcaps} STI571 or vehicle as control (Ctr). We used three independent short hairpin RNA (shRNA) to generate three mass SOS1-KD populations (see [Supplementary Methods](#sup1){ref-type="supplementary-material"}), which gave similar results. Cell Lysates were incubated for 1 h with 20 μg of GST-CRIB to pull down GTP-loaded RAC and immunoblotted to detect activated RAC. (**b**) An equal number (50 000 cells/ml) of K562 control cells (Ctr), STI571-treated, NSC2376-treated or SOS1-KD cells (SOS1 KD) were plated and counted at the indicated times. Data are the mean±s.e.m. of four independent experiments done in triplicates. (**c**). An equal number (100 000 cells/ml) of control (Ctr), or STI571-treated or SOS1-KD K562cells (SOS1 KD) were plated in soft agar. Upper panels, representative pictures of the colonies obtained after 14 days. Lower graphs, quantification of colony number (left) and colony diameter (right). At least 50 colonies were counted. Data are the mean±s.e.m (*n*=3 independent experiments). \*\**P\<*0.005 Student's *t*-test. Scale bar, 200 μm. (**d**) An equal number (5 × 10^5^) of control and SOS-1 KD K562 were injected into the tail vein of immunodeficient mice. Mice were monitored for survival (*n*=15 of a representative experiment run in duplicate). *P*-values (Pearson) were measured by *χ*^2^-test.](leu2017267f4){#fig4}

![*Sos*1 deletion abolishes BCR-ABL induced transformation of HSCs *in vitro* and delays leukemogenesis *in vivo*. (**a**) 5-FU enriched BMDCs were retrovirally-infected with pMigBCR-ABL^p210^ before being treated with (SOS1^KO^) or without (SOS1^fl/fl^) tamoxifen and transplanted into lethally irradiated recipient mice. Recipient mice were injected i.p. with tamoxifen or solvent for 2 days after TX to induce *Sos1* deletion and monitored for leukemia induction. Tamoxifen had no effect on cell engraftment or leukemic development (not shown). In addition, it did not affect the efficiency of infection, which was about 20% in the presence or the absence of TX (not shown). Kaplan--Meier plot details the overall survival of transplanted mice (*n*=6) of 2 independent experiments. *P*-value was determined by log-rank test. (**b** and **c**). Peripheral blood measurement of mice that received a *Sos1* deleted BMDC transplant showed a significantly reduction in leukemic white blood cells (**b**) gain, as well as a reduced leukemic burden (**c**) of *Sos1* deleted BMDCs transplanted mice during the course of disease. Results are from a representative transplantation experiment (*n*=6) out of two independent ones at the indicated time points. Leukemic burden was measured by the percentage of enhanced green fluorescent protein (EGFP)-positive CD45 cells in the PB. *P*-values were determined by Student's *t*-test: \**P*\<0.05, \*\**P*\<0.01 and \*\*\**P*\<0.005.](leu2017267f5){#fig5}
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